This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) fourth-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Sanofi, J&J Join Forces With BARDA for Coronavirus Vaccine
by Zacks Equity Research
Sanofi (SNY) and J&J (JNJ) sign deals with BARDA, part of U.S. Department of Health and Human Services, for accelerated development of a vaccine for the newly found coronavirus.
Top Research Reports for Facebook, Netflix & NextEra Energy
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Netflix (NFLX) and NextEra Energy (NEE).
Regeneron Reports Positive Eylea Data From Late-Stage Study
by Zacks Equity Research
Regeneron (REGN) announces positive two-year results from the phase III PANORAMA study on lead ophthalmology drug, Eylea.
Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split
by Kinjel Shah
Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.
Alnylam's (ALNY) Q4 Earnings Miss Estimates, Sales Beat
by Zacks Equity Research
Alnylam (ALNY) posts a wider-than-expected loss, while revenues beat estimates marginally in the fourth quarter of 2019.
Sanofi (SNY) Q4 Earnings Top, Sales Miss, Dupixent Strong
by Zacks Equity Research
Sanofi (SNY) reports mixed fourth-quarter results with strong Specialty Care and Vaccines sales but soft Consumer Healthcare sales
Regeneron's (REGN) Q4 Earnings & Sales Surpass Estimates
by Zacks Equity Research
Regeneron (REGN) beats on Q4 earnings and sales on solid performance of ophthalmology drug, Eylea, and asthma drug, Dupixent.
Novo Nordisk (NVO) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Novo Nordisk (NVO) posts in-line earnings, while revenues beat estimates in the fourth quarter of 2019.
Why Earnings Season Could Be Great for Sanofi (SNY)
by Zacks Equity Research
Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off
by Zacks Equity Research
Merck (MRK) beats estimates for earnings but misses the same for sales in fourth-quarter 2019. The company plans to spin off Women Health drugs/biosimilars into new company. Shares down.
Merck's Recarbrio Gets FDA Priority Review for New Indication
by Zacks Equity Research
The FDA accepts Merck's (MRK) sNDA for antibacterial injection Recarbrio and grants priority review.
Will Eylea & Dupixent Drive Regeneron's (REGN) Q4 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports fourth-quarter 2019 results.
Lilly's NDA for Selpercatinib Gets FDA's Priority Review
by Zacks Equity Research
Lilly's (LLY) NDA for oral RET inhibitor selpercatinib gains the FDA priority review status for RET-altered lung and thyroid cancers.
Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data
by Zacks Equity Research
It has been a busy week for the biotech sector with pipeline and regulatory updates from quite a few players.
Are Investors Undervaluing Sanofi (SNY) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
SNY vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SNY vs. NVO: Which Stock Is the Better Value Option?
Regeneron & Sanofi's sBLA for Dupixent Accepted by the FDA
by Zacks Equity Research
The FDA accepts Regeneron (REGN) and Sanofi's sBLA for Dupixent for Priority Review.
Lilly's Olumiant Meets Primary Goal in Dermatitis Study
by Zacks Equity Research
Eli Lilly (LLY) and partner Incyte's Olumiant meets primary endpoint in atopic dermatitis in a late-stage study.
Dr. Reddy's (RDY) Q3 Earnings and Revenues Increase Y/Y
by Zacks Equity Research
Dr. Reddy's (RDY) earnings (excluding impairment charge) increase year over year in the third quarter of fiscal 2020.
The Zacks Analyst Blog Highlights: Merck, Broadcom, Sanofi, Equinix and American Electric Power
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Broadcom, Sanofi, Equinix and American Electric Power
Top Stock Analyst Reports for Merck, Broadcom & Sanofi
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Broadcom (AVGO) and Sanofi (SNY).
Should Value Investors Pick Sanofi (SNY) Stock Right Now?
by Zacks Equity Research
Is Sanofi (SNY) a great pick from the value investor's perspective right now? Read on to know more.
Novavax Rises on Fast Track Designation to Influenza Vaccine
by Zacks Equity Research
The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.
Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins
by Zacks Equity Research
Eli Lilly (LLY) announced plans to launch cheaper version of its Humalog insulins, Mix75/25 KwikPen and Junior KwikPen.